Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

International Thymic Malignancy Interest Group

International Thymic Malignancy Interest Group EDITORIAL Frank Detterbeck, MD,* Giuseppe Giaccone, MD,† Patrick Loehrer, MD,‡ Saul Suster, MD,§ and Cameron Wright, MD hymomas and thymic carcinomas are rare tumors that are complex, with issues Trelated to associated conditions, involved structures, understanding of the biology, and definition of the optimal treatment. Currently, data stem from single centers, with reports generally spanning many decades, and level 1 evidence is lacking. To make progress in the treatment and understanding of these unique malignancies, there is a need for an organized collaborative effort, which necessitates creation of an interna- tional infrastructure. To enhance international teamwork, the Foundation for Thymic Cancer Re- search organized two meetings of many of the leaders in this field (in New York in 2007 and at MD Anderson in 2008). The Foundation is a patient and family organization focused on both patient advocacy and promotion of research. These meetings led to several collaborative initiatives and publications, including several 2,3 4 meta-analyses and NCCN guidelines for the management of thymic malignancies. These meetings also highlighted the need for greater infrastructure to foster true prospective collaboration. A nucleus of individuals has developed this concept and initiated the process. An initial focal point was to organize an http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

International Thymic Malignancy Interest Group

Journal of Thoracic Oncology , Volume 5 (1) – Jan 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/international-thymic-malignancy-interest-group-0FY4g0c4To

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181c59224
pmid
20035184
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Frank Detterbeck, MD,* Giuseppe Giaccone, MD,† Patrick Loehrer, MD,‡ Saul Suster, MD,§ and Cameron Wright, MD hymomas and thymic carcinomas are rare tumors that are complex, with issues Trelated to associated conditions, involved structures, understanding of the biology, and definition of the optimal treatment. Currently, data stem from single centers, with reports generally spanning many decades, and level 1 evidence is lacking. To make progress in the treatment and understanding of these unique malignancies, there is a need for an organized collaborative effort, which necessitates creation of an interna- tional infrastructure. To enhance international teamwork, the Foundation for Thymic Cancer Re- search organized two meetings of many of the leaders in this field (in New York in 2007 and at MD Anderson in 2008). The Foundation is a patient and family organization focused on both patient advocacy and promotion of research. These meetings led to several collaborative initiatives and publications, including several 2,3 4 meta-analyses and NCCN guidelines for the management of thymic malignancies. These meetings also highlighted the need for greater infrastructure to foster true prospective collaboration. A nucleus of individuals has developed this concept and initiated the process. An initial focal point was to organize an

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jan 1, 2010

There are no references for this article.